Wilfried A M Bakker

Summary

Affiliation: National Institute for Public Health and the Environment
Country: The Netherlands

Publications

  1. doi Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV
    Wilfried A M Bakker
    National Institute for Public Health and the Environment, Vaccinology Unit, P O Box 1, 3720BA Bilthoven, The Netherlands
    Vaccine 29:7188-96. 2011
  2. doi Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines
    Janny Westdijk
    National Institute for Public Health, Unit Vaccinology, Antonie van Leeuwenhoeklaan 9, 3720 AL Bilthoven, The Netherlands
    Vaccine 29:3390-7. 2011
  3. doi Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains
    Pauline Verdijk
    Vaccinology Unit, RIVM, Antonie van Leeuwenhoeklaan 9, PO Box 1, 3720 BA Bilthoven, The Netherlands
    Expert Rev Vaccines 10:635-44. 2011
  4. ncbi Innovative IPV from attenuated Sabin poliovirus or newly designed alternative seed strains
    Ahd Hamidi
    National Institute for Public Health and the Environment RIVM, Centre for Infectious Disease Control CIb, Vaccinology Unit, P O Box 1, 3720 BA Bilthoven, The Netherlands
    Pharm Pat Anal 1:589-99. 2012

Collaborators

Detail Information

Publications4

  1. doi Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV
    Wilfried A M Bakker
    National Institute for Public Health and the Environment, Vaccinology Unit, P O Box 1, 3720BA Bilthoven, The Netherlands
    Vaccine 29:7188-96. 2011
    ..Finally, the planned technology transfer to vaccine manufacturers in low and middle-income countries is discussed...
  2. doi Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines
    Janny Westdijk
    National Institute for Public Health, Unit Vaccinology, Antonie van Leeuwenhoeklaan 9, 3720 AL Bilthoven, The Netherlands
    Vaccine 29:3390-7. 2011
    ..The latter observations are in line with data from human trials. This suggests that a higher dose of Sabin-IPV type 2 to compensate for the lower rat immunogenicity may not be necessary...
  3. doi Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains
    Pauline Verdijk
    Vaccinology Unit, RIVM, Antonie van Leeuwenhoeklaan 9, PO Box 1, 3720 BA Bilthoven, The Netherlands
    Expert Rev Vaccines 10:635-44. 2011
    ..Sabin-IPV is under development by several manufacturers. This article gives an overview of results from clinical trials with Sabin-IPV and discusses the requirements and challenges in the clinical development of this novel IPV...
  4. ncbi Innovative IPV from attenuated Sabin poliovirus or newly designed alternative seed strains
    Ahd Hamidi
    National Institute for Public Health and the Environment RIVM, Centre for Infectious Disease Control CIb, Vaccinology Unit, P O Box 1, 3720 BA Bilthoven, The Netherlands
    Pharm Pat Anal 1:589-99. 2012
    ..Currently, such work is mainly carried out by research institutes and universities and therefore clinical data are not available. ..